- Home
- PLUR vs OTLK Comparison
PLUR vs OTLK Comparison
Compare PLUR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | OTLK |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 29.2M |
| IPO Year | 2001 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PLUR | OTLK |
|---|---|---|
| Price | $3.35 | $0.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $2.50 |
| AVG Volume (30 Days) | 4.3K | ★ 4.4M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.78 | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | $1,336,000.00 | ★ $8,146,123.00 |
| Revenue This Year | $97.38 | $1,430.98 |
| Revenue Next Year | $293.97 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $0.16 |
| 52 Week High | $6.10 | $3.39 |
Technical Indicators
Market Signals| Indicator | PLUR | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 52.38 |
| Support Level | $3.12 | $0.17 |
| Resistance Level | $3.42 | $0.46 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 21.64 | 62.21 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.